AU2021278157B2 - Dual-agonist compound for both GLP-1 and GIP receptors and application thereof - Google Patents

Dual-agonist compound for both GLP-1 and GIP receptors and application thereof

Info

Publication number
AU2021278157B2
AU2021278157B2 AU2021278157A AU2021278157A AU2021278157B2 AU 2021278157 B2 AU2021278157 B2 AU 2021278157B2 AU 2021278157 A AU2021278157 A AU 2021278157A AU 2021278157 A AU2021278157 A AU 2021278157A AU 2021278157 B2 AU2021278157 B2 AU 2021278157B2
Authority
AU
Australia
Prior art keywords
glp
amino acid
amino
analog
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021278157A
Other languages
English (en)
Other versions
AU2021278157A1 (en
Inventor
Haiqing Hua
Xuchao Huang
Renzhi Liu
Lei Wang
Fangzhou WU
Ran WU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Pharmaceutical Co Ltd
Publication of AU2021278157A1 publication Critical patent/AU2021278157A1/en
Assigned to JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. reassignment JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. Request for Assignment Assignors: BEIJING TUO JIE BIOPHARMACEUTICAL CO. LTD.
Application granted granted Critical
Publication of AU2021278157B2 publication Critical patent/AU2021278157B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2021278157A 2020-05-29 2021-05-28 Dual-agonist compound for both GLP-1 and GIP receptors and application thereof Active AU2021278157B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202010472577.8 2020-05-29
CN202010472577 2020-05-29
CN202110335100 2021-03-29
CN202110335100.X 2021-03-29
PCT/CN2021/096568 WO2021239082A1 (zh) 2020-05-29 2021-05-28 Glp-1和gip受体双重激动剂化合物及其应用

Publications (2)

Publication Number Publication Date
AU2021278157A1 AU2021278157A1 (en) 2022-11-24
AU2021278157B2 true AU2021278157B2 (en) 2026-08-06

Family

ID=78745631

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021278157A Active AU2021278157B2 (en) 2020-05-29 2021-05-28 Dual-agonist compound for both GLP-1 and GIP receptors and application thereof

Country Status (11)

Country Link
US (1) US12653865B2 (cg-RX-API-DMAC7.html)
EP (1) EP4159750A4 (cg-RX-API-DMAC7.html)
JP (1) JP7858549B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230018395A (cg-RX-API-DMAC7.html)
CN (3) CN118754965A (cg-RX-API-DMAC7.html)
AU (1) AU2021278157B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022023834A2 (cg-RX-API-DMAC7.html)
CA (1) CA3180215A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022014368A (cg-RX-API-DMAC7.html)
TW (1) TWI910174B (cg-RX-API-DMAC7.html)
WO (1) WO2021239082A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
CA3231953A1 (en) 2021-09-15 2023-03-23 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
CN118103391A (zh) * 2021-11-12 2024-05-28 福建盛迪医药有限公司 Glp-1受体和gip受体双重激动剂的药物组合物及其用途
CN116970063A (zh) * 2022-04-29 2023-10-31 苏州星洲生物科技有限公司 Glp-1/gip受体共激动剂、包含其的药物组合物及其用途
CN117402219B (zh) * 2022-07-13 2024-07-30 杭州中美华东制药有限公司 Glp-1/gip双激动剂及其制备方法和用途
CN115806593B (zh) * 2022-09-23 2023-09-05 成都普康生物科技有限公司 一种脂肪酸链修饰的双受体激动剂及其用途
CN116120425A (zh) * 2022-12-27 2023-05-16 南京赛诺生物技术有限公司 一种glp-1/gip受体双重激动剂及其应用
WO2024153090A1 (zh) * 2023-01-17 2024-07-25 广东众生睿创生物科技有限公司 基于glp-1的三重激动剂
CN118684758A (zh) * 2023-03-23 2024-09-24 上海民为生物技术有限公司 肠促胰岛素类似物及其应用
CN116496361B (zh) * 2023-06-25 2023-09-15 北京科翔中升医药科技有限公司 氘代模拟肽gip和glp-1双受体激动剂药物及用途
WO2025124473A1 (zh) 2023-12-12 2025-06-19 江苏恒瑞医药股份有限公司 Glp-1类似物治疗代谢疾病的方法及医药用途
WO2025242218A1 (zh) * 2024-05-24 2025-11-27 上海翰森生物医药科技有限公司 一种多肽激动剂,其制备方法及医药用途
CN119390784B (zh) * 2024-07-11 2026-06-30 中国药科大学 一种双激动多肽化合物及其医药用途
CN118546214B (zh) * 2024-07-11 2024-12-03 中国药科大学 Glp-1r受体激动多肽化合物及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012167744A1 (en) * 2011-06-10 2012-12-13 Beijing Hanmi Pharmaceutical Co., Ltd. Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
WO2014096145A1 (en) * 2012-12-21 2014-06-26 Sanofi Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
WO2020207477A1 (zh) * 2019-04-11 2020-10-15 江苏豪森药业集团有限公司 Glp-1和gip受体双重激动剂化合物及其应用
CN111825758A (zh) * 2019-04-19 2020-10-27 上海翰森生物医药科技有限公司 Glp-1和gip共激动剂化合物

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
EP2007804B1 (en) 2006-04-20 2014-06-18 Amgen, Inc Glp-1 compounds
US20120329711A1 (en) 2009-12-16 2012-12-27 Nordisk A/S Glp-1 receptor agonist compounds with a modified n-terminus
RU2013133803A (ru) 2010-12-22 2015-01-27 Маркадиа Байотек, Инк. Способы лечения метаболических нарушений и ожирения при помощи пептидов на основе глюкагона, активных по отношению к рецепторам гип и гпп
ES2602486T3 (es) 2012-06-21 2017-02-21 Indiana University Research And Technology Corporation Análogos de glucagón que muestran actividad de receptor de GIP
CN104981186A (zh) 2012-12-12 2015-10-14 意特发展有限公司 发泡器、混合器
CN108271356A (zh) 2014-09-24 2018-07-10 印第安纳大学研究及科技有限公司 肠降血糖素-胰岛素缀合物
JP6581656B2 (ja) * 2014-10-24 2019-09-25 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. グルカゴンおよびglp−1受容体のコアゴニスト
AR103242A1 (es) 2015-01-09 2017-04-26 Lilly Co Eli Compuestos co-agonistas de gip y glp-1
WO2016131893A1 (en) 2015-02-18 2016-08-25 Medimmune Limited Incretin fusion polypeptides
JP6712323B2 (ja) 2015-12-31 2020-06-17 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン、glp−1及びgip受容体のすべてに活性を有する三重活性体
WO2017149070A1 (en) 2016-03-03 2017-09-08 Novo Nordisk A/S Glp-1 derivatives and uses thereof
CA3062194A1 (en) 2017-06-20 2018-12-27 Amgen Inc. Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
JP7250706B2 (ja) 2017-06-21 2023-04-03 アムジエン・インコーポレーテツド 胃抑制ペプチド受容体(gipr)に対するアンタゴニスト結合タンパク質/glp-1受容体アゴニスト融合タンパク質を使用した代謝障害の治療又は寛解方法
US20210087250A1 (en) 2018-04-06 2021-03-25 Cyprumed Gmbh Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
TWI705820B (zh) 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
AU2019309798A1 (en) 2018-07-23 2021-02-11 Eli Lilly And Company Method of using a GIP/GLP1 co-agonist for diabetes
KR20250044806A (ko) 2018-07-23 2025-04-01 일라이 릴리 앤드 캄파니 요법을 위한 gip/glp1 공효능제 사용 방법
ES3068975T3 (en) 2018-07-23 2026-06-03 Lilly Co Eli Gip/glp1 co-agonist compounds
EP3856768A2 (en) 2018-09-24 2021-08-04 Takeda Pharmaceutical Company Limited Gip receptor agonist peptide compounds and uses thereof
US20220016215A1 (en) 2018-09-24 2022-01-20 Takeda Phaarmaceutical Company Limited Gip receptor agonist peptide compounds and uses thereof
TW202120535A (zh) 2019-11-15 2021-06-01 大陸商江蘇豪森藥業集團有限公司 受體雙重激動劑化合物及其醫藥組成物
EP4069726A4 (en) 2019-12-04 2024-03-20 The Scripps Research Institute GLP2 RECEPTOR AGONISTS AND METHOD OF USE
IL296592A (en) 2020-03-25 2022-11-01 Takeda Pharmaceuticals Co Qd dosing of gip receptor agonist peptide compounds and uses thereof
TW202216746A (zh) 2020-06-22 2022-05-01 印度商太陽製藥工業有限公司 長效型glp-1/gip雙重促效劑
JP2023534130A (ja) 2020-07-22 2023-08-08 ノヴォ ノルディスク アー/エス Glp-1受容体およびgip受容体共作動薬
AU2021312323A1 (en) 2020-07-22 2023-02-02 Novo Nordisk A/S Co-agonists at GLP-1 and GIP receptors suitable for oral delivery
CN116171164A (zh) 2020-10-17 2023-05-26 太阳医药工业有限公司 Glp-1/gip双重激动剂
CA3213261A1 (en) 2021-03-25 2022-09-29 Jiandong Yuan Gip and glp-1 dual receptor agonist, pharmaceutical composition, and use
AU2022289610A1 (en) 2021-06-09 2024-01-25 The Scripps Research Institute Long-acting dual gip/glp-1 peptide conjugates and methods of use
CN115521368B (zh) 2021-06-25 2024-08-23 江苏鸿永医药技术有限公司 毒蜥外泌肽-4衍生物
WO2024192219A1 (en) 2023-03-15 2024-09-19 Viking Therapeutics, Inc. Pharmaceutical compositions and methods for the treatment of metabolic and liver disorders
WO2025024788A1 (en) 2023-07-27 2025-01-30 Biomedit, Llc Stabilized glp-1 peptides and dual agonist peptides against glp-1r and gipr and methods of use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012167744A1 (en) * 2011-06-10 2012-12-13 Beijing Hanmi Pharmaceutical Co., Ltd. Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
WO2014096145A1 (en) * 2012-12-21 2014-06-26 Sanofi Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
WO2020207477A1 (zh) * 2019-04-11 2020-10-15 江苏豪森药业集团有限公司 Glp-1和gip受体双重激动剂化合物及其应用
CN111825758A (zh) * 2019-04-19 2020-10-27 上海翰森生物医药科技有限公司 Glp-1和gip共激动剂化合物

Also Published As

Publication number Publication date
US20230190879A1 (en) 2023-06-22
CN114222755A (zh) 2022-03-22
EP4159750A4 (en) 2023-10-18
KR20230018395A (ko) 2023-02-07
JP7858549B2 (ja) 2026-05-14
JP2023526973A (ja) 2023-06-26
BR112022023834A2 (pt) 2022-12-27
WO2021239082A1 (zh) 2021-12-02
TWI910174B (zh) 2026-01-01
CN118754965A (zh) 2024-10-11
EP4159750A1 (en) 2023-04-05
CA3180215A1 (en) 2021-12-02
CN114222755B (zh) 2024-06-11
TW202144393A (zh) 2021-12-01
CN118530333A (zh) 2024-08-23
US12653865B2 (en) 2026-06-16
AU2021278157A1 (en) 2022-11-24
MX2022014368A (es) 2022-12-15

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.

Free format text: FORMER APPLICANT(S): BEIJING TUO JIE BIOPHARMACEUTICAL CO. LTD.